CLS’ products and method are planned to be used in a clinical trial, carried out by Immunophotonics, regarding evaluation of new drug
Clinical Laserthermia Systems AB (publ) (CLS) is preparing to enter into an agreement under which the company’s technology and products will be used in a clinical trial, carried out by the American biotech company Immunophotonics Inc. The purpose of the trial is to evaluate the efficacy of a new IP-001-drug from Immunophotonics, developed to create, or enhance, an immune response in connection with ablation treatment. The trial, planned to be carried out at a number of hospitals in Switzerland, will be financed by Immunophotonics. More information about the collaboration will be announced when the parties have signed the agreement.
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Irvine, CA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser:Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: ca@vhcorp.se. Further information is available on www.clinicallaser.se